Nuclear medicine imaging of neuroendocrine tumours

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 12, Issue 4, 2012, Pages 377-380

  Al Nahhas, Adil ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Gallium 68 Dotatate; Indium 111 octreotide; Neuroendocrine tumours; PET CT imaging; Somatostatin receptors

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 5 HYDROXYTRYPTOPHAN C 11; 6 FLUORODOPA F 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONVENTIONAL ANGIOGRAPHY; DIAGNOSTIC IMAGING; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FUNCTIONAL NEUROIMAGING; HUMAN; NEUROENDOCRINE TUMOR; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR DIAGNOSIS; ULTRASOUND;

EID: 84865485341     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.12-4-377     Document Type: Article

References (20)

1. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004;80(Suppl 1):3-7. (Pubitemid 39382359)
2. Weckbecker G, Lewis I, Albert R et al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003;2:999-1017. (Pubitemid 37540581)
3. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Review. Endocr Rev 1991;12:450-82.
4. Reubi JC, Schär JC, Waser B et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82. (Pubitemid 30167697)
5. Krenning EP, Kwekkeboom DJ, Bakker WH et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Review. Eur J Nucl Med 1993;20:716-31. (Pubitemid 23284773)
6. Ezziddin S, Logvinski T, Yong-Hing C et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2006;47:223-33. (Pubitemid 46780886)
7. Bombardieri E, Seregni E, Villano C et al. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Review. Q J Nucl Med Mol Imaging 2004;48:150-63. (Pubitemid 39248302)
8. Prasad V, Ambrosini V, Alavi A et al. PET/CT in neuroendocrine tumors: evaluation of receptor status and metabolism. PET Clin 2007;2:351-75.
9. Hoegerle S, Altehoefer C, Ghanem N et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220:373-80. (Pubitemid 32667172)
10. Orlefors H, Sundin A, Garske U et al. Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-400. (Pubitemid 41014303)
11. Hofmann M, Maecke H, Börner R et al. Biokinetics and imaging with the somato-statin receptor PET radioligand (68) Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751-7.
12. Al-Nahhas A, Win Z, Szyszko T et al. Gallium-68 PET: a new frontier in receptor cancer imaging. Review. Anticancer Res 2007;27:4087-94.
13. Gabriel M, Decristoforo C, Kendler D et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18. (Pubitemid 47571404)
14. Kayani I, Bomanji JB, Groves A et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447-55.
15. Ambrosini V, Rubello D, Nanni C et al. 68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients. Nucl Med Commun 2008;29:415-7. (Pubitemid 351507533)
16. Ambrosini V, Tomassetti P, Castellucci P et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431-8.
17. Naji M, Zhao C, Welsh SJ et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 2011;13:769-75.
18. Naji M, Al-Nahhas A. 68Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging 2012;39(Suppl 1):S61-7.
19. Putzer D, Gabriel M, Henninger B et al. Bone metastases in patients with neuroendocrine tumour: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-21.
20. Al-Nahhas A. Detection of unsuspected bone metastases by 68Ga-DOTA: nuclear medicine at the forefront again. Nucl Med Commun 2011;32:877-9.